Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belimumab - AstraZeneca/GSK

Next Previous
X
Search
Drug Profile

Belimumab - AstraZeneca/GSK

Alternative Names: Anti-BLyS monoclonal antibody; Benlysta; BmAb; GSK1550188; HGS-1006; LSB; LymphoStat-B; monoclonal anti-BLyS

Latest Information Update: 11 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology; Human Genome Sciences
  • Developer Assistance Publique Hopitaux de Paris; Cancer Trials Australia; GlaxoSmithKline; GSK; Hospital for Special Surgery; Human Genome Sciences; National Institute of Allergy and Infectious Diseases; North Shore-Long Island Jewish Health System; University of Pennsylvania; University of Wisconsin-Madison; Washington University School of Medicine
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic lupus erythematosus
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lupus nephritis; Systemic lupus erythematosus
  • Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis; Interstitial lung diseases
  • Phase II/III Myositis; Systemic scleroderma
  • Phase II Membranous glomerulonephritis; Multiple sclerosis; Myasthenia gravis; Renal transplant rejection
  • No development reported Graft-versus-host disease; Waldenstrom's macroglobulinaemia
  • Discontinued Rheumatoid arthritis; Sjogren's syndrome

Most Recent Events

  • 04 Dec 2024 GlaxoSmithKline plans a phase III trial for Interstitial lung diseases (systemic sclerosis associated interstitial lung disease) in Argentina, Belgium, Brazil, China, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, South Korea, Spain (SC, Injection) (NCT06716606)
  • 26 Aug 2024 Phase-III clinical trials in Interstitial lung diseases (Treatment-experienced) in Japan (SC) (NCT06572384) (EudraCT2024-513018-36)
  • 04 Dec 2023 700361548: Updated KDM, added devlines and HE.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top